S-3: Registration statement under Securities Act of 1933
Published on November 18, 2026
As filed with the Securities and Exchange Commission on November 18, 2026
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM S-3
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
Abeona Therapeutics Inc.
(Exact name of registrant as specified in its charter)
| Delaware | 83-0221517 | |
| (State
or other jurisdiction of incorporation or organization) |
(I.R.S.
Employer Identification No.) |
6555 Carnegie Ave, 4th Floor,
Cleveland, OH 44103
(646) 813-4701
(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)
Joseph Vazzano
Chief Financial Officer
Abeona Therapeutics Inc.
6555 Carnegie Avenue, 4th Floor
Cleveland, OH 44103
(646) 813-4701
(Name, address, including zip code, and telephone number, including area code, of agent for service)
Copies to:
Brian V. Soares
Carlton Fields, P.A.
4221 W Boy Scout Blvd., Suite 1000
Tampa, FL 33607
(813) 223-7000
Approximate date of commencement of proposed sale to the public: From time to time after the effective date of this Registration Statement.
If the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check the following box: ☐
If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, as amended, other than securities offered only in connection with dividend or interest reinvestment plans, check the following box: ☒
If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering: ☐
If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earliest effective registration statement for the same offering: ☐
If this Form is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box: ☐
If this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I. D. filed to register additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following box: ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act:
| Large accelerated filer | ☐ | Accelerated filer | ☐ |
| Non-accelerated filer | ☒ | Smaller reporting company | ☒ |
| Emerging growth company | ☐ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐
The Registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment that specifically states that this registration statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933, as amended, or until this registration statement shall become effective on such date as the Commission, acting pursuant to said Section 8(a), may determine.
The information in this prospectus is not complete and may be changed. The selling stockholders named in this prospectus may not sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities, and it is not soliciting an offer to buy these securities, in any jurisdiction where the offer or sale is not permitted.
SUBJECT TO COMPLETION, DATED NOVEMBER 18, 2026
PROSPECTUS

Abeona Therapeutics Inc.
12,494,426 Shares
Common Stock
Offered by the Selling Stockholders
This prospectus relates to the proposed resale or other disposition by the selling stockholders identified herein (the “Selling Stockholders”), of up to 12,494,426 shares of our common stock, par value $0.01 per share (“Common Stock”), which consists of (i) 4,494,383 shares (“Acquisition Shares”) issued to Ellodi Pharmaceuticals, L.P., a Delaware limited partnership (“Ellodi Pharmaceuticals”) in connection with the Company’s acquisition of certain assets relating to APT-1011 (the “Acquisition”), (ii) 6,400,000 shares of Common Stock (the “Private Placement Shares”) issued to the purchasers pursuant to the Securities Purchase Agreement dated November 6, 2026, by and among the Company and the purchasers signatory thereto (the “Securities Purchase Agreement”), and (iii) 1,600,043 shares of Common Stock issuable upon the exercise of outstanding pre-funded warrants to purchase shares of Common Stock (the “Pre-Funded Warrants”) issued to the applicable Selling Stockholders in connection with the closing of the Private Placement, as defined below (the “Pre-Funded Warrant Shares”). The shares of Common Stock registered by this prospectus are referred to herein as the “Resale Shares.”
The Acquisition Shares were issued to Ellodi Pharmaceuticals pursuant to that certain Asset Purchase Agreement, dated November 6, 2026, by and between the Company and Ellodi Pharmaceuticals (the “Asset Purchase Agreement”). The Private Placement Shares and the Pre-Funded Warrants were issued and sold to accredited investors (the “Investors”) in a private placement (the “Private Placement”).
We are not offering or selling any Resale Shares under this prospectus and will not receive any of the proceeds from the sale or other disposition of Resale Shares by the Selling Stockholders.
We have agreed to bear all of the expenses incurred in connection with the registration of these shares. The selling stockholders will pay or assume discounts, commissions, transfer taxes, fees of underwriters, selling brokers or dealer managers and similar other costs and expenses, if any, incurred for the offer and sale of these shares of our common stock.
The Selling Stockholders identified in this prospectus may offer the Resale Shares from time to time on terms to be determined at the time of sale through ordinary brokerage transactions or through any other means described in this prospectus under the caption “Plan of Distribution.” The Resale Shares may be sold at fixed prices, at prevailing market prices at the time of sale, at prices related to the prevailing market price, at varying prices determined at the time of sale or at negotiated prices. The Selling Stockholders may sell Resale Shares to or through underwriters, broker-dealers or agents, who may receive compensation in the form of discounts, concessions or commissions from the Selling Stockholders, the purchasers of the shares, or both. For a list of the selling stockholders, see the section entitled “Selling Stockholders” on page 8 of this prospectus.
The Selling Stockholders may sell any, all or none of the securities offered by this prospectus and we do not know when or in what amount the Selling Stockholders may sell their Resale Shares hereunder following the effective date of the registration statement of which this prospectus forms a part.
You should carefully read this prospectus and any applicable prospectus supplement, as well as any documents incorporated by reference herein or therein, before you invest in any of the securities being offered.
Our Common Stock is traded on the Nasdaq Capital Market under the symbol “ABEO.” On November 16, 2026, the last reported sales price for our Common Stock was $2.60 per share.
An investment in our securities involves a high degree of risk. You should carefully consider the information under the heading “Risk Factors” beginning on page 6 of this prospectus and any applicable prospectus supplement, and under similar headings in the other documents that are incorporated by reference into this prospectus.
Neither the SEC nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense. The securities are not being offered in any jurisdiction where the offer is not permitted.
The date of this prospectus is , 2026
| i |
This prospectus is part of a registration statement on Form S-3 that we filed with the SEC using a “shelf” registration process. Under this shelf registration process, the Selling Stockholders may, from time to time, offer and sell the securities described in this prospectus in one or more offerings. Information about the Selling Stockholders may change over time.
This prospectus provides you with a general description of the securities the Selling Stockholders may offer. Each time the Selling Stockholders sell shares of Common Stock using this prospectus, to the extent necessary and required by law, we will provide a prospectus supplement that will contain specific information about the terms of that offering, including the number of shares of Common Stock being offered, the manner of distribution, the identity of any underwriters or other counterparties and other specific terms related to the offering. The prospectus supplement may also add, update or change information contained in this prospectus. To the extent that any statement made in a prospectus supplement is inconsistent with statements made in this prospectus, the statements made in this prospectus will be deemed modified or superseded by those made in the prospectus supplement. You should read this prospectus, any applicable prospectus supplement and the information incorporated by reference in this prospectus before making an investment in shares of our Common Stock. See “Where You Can Find More Information” for more information.
This prospectus contains and incorporates by reference information that you should consider when making your investment decision. Neither we nor the Selling Stockholders have authorized anyone to give any information or to make any representation other than those contained or incorporated by reference in this prospectus. The Selling Stockholders are offering to sell, and seeking offers to buy, our securities only in jurisdictions where it is lawful to do so. We have not authorized anyone to provide you with different information. This prospectus and any accompanying prospectus supplement do not constitute an offer to sell or the solicitation of an offer to buy any securities other than the securities described in any accompanying prospectus supplement or an offer to sell or the solicitation of an offer to buy such securities in any circumstances in which such offer or solicitation is unlawful. You should assume that the information appearing in this prospectus, any prospectus supplement, the documents incorporated by reference herein and any related free writing prospectus is accurate only as of their respective dates. Our business, financial condition, results of operations and prospects may have changed materially since those dates.
In this prospectus, unless the context otherwise requires, references to the terms “the Company,” “Abeona,” “we,” “our” and “us” or other similar terms mean Abeona Therapeutics Inc., unless we state otherwise or the context indicates otherwise.
This prospectus contains references to our trademarks, trade names and service marks, such as “ZEVASKYN®,” which are protected under applicable intellectual property laws and are the property of Abeona Therapeutics Inc. or its subsidiaries. Solely for convenience, trademarks, trade names and service marks referred to in this prospectus appear without the ® and ™ symbols, but such references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or the right of the applicable licensor to these trademarks, trade names and service marks. We do not intend our use or display of other parties’ trademarks, trade names or service marks to imply, and such use or display should not be construed to imply, a relationship with, or endorsement or sponsorship of us by, these other parties.
For investors outside of the United States, neither we nor the Selling Stockholders have done anything that would permit the offering or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than in the United States. You are required to inform yourselves about and to observe any restrictions relating to the offering and the distribution of this prospectus outside of the United States.
| 1 |
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS
This prospectus, including the documents that we incorporate by reference, contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). These forward-looking statements involve a number of risks and uncertainties. We caution readers that any forward-looking statement is not a guarantee of future performance and that actual results could differ materially from those contained in the forward-looking statement. These statements are based on current expectations of future events.
All statements, other than statements of historical facts contained in this prospectus, are forward-looking statements, including, without limitation, statements regarding: the commercialization of ZEVASKYN® and generation of future revenue; our ability to realize the anticipated benefits of the Company’s acquisition of ABO-801, including the integration of ABO-801 into our business; the development of ABO-801 (formerly APT-1011) and ABO-701; our pipeline of product candidates, including the achievement of or expected timing, progress and results of clinical development, clinical trials and potential regulatory approvals; our estimates regarding expenses, capital requirements, and needs for additional financing; anticipated losses and negative cash flows; the potential effects on the relative equity ownership of existing investors resulting from any future sales of equity securities; the potential effects of fundraising activities involving collaborations, strategic alliances, licensing arrangements or asset dispositions with third parties; our intended use of cash; our intellectual property position and our ability to obtain, maintain and enforce intellectual property protection and exclusivity for our proprietary assets; and future economic conditions or performance. Forward-looking statements generally relate to future events or our future financial or operating performance. The words “anticipate,” “can,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “will,” and “would,” or the negative of such terms or other similar expressions that convey uncertainty of future events or outcomes, are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.
These forward-looking statements are subject to a number of risks, uncertainties and assumptions. Moreover, we operate in a very competitive and rapidly changing environment, and new risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. Factors that might cause such a difference include those discussed in our most recent Annual Report on Form 10-K, as supplemented and updated by subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K that we have filed or will file with the SEC, and in other documents which are incorporated by reference into this prospectus, as well as the risk factors and other information contained in or incorporated by reference into any accompanying prospectus supplement. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this prospectus or, in the case of documents referred to or incorporated by reference, the date of those documents.
In addition, statements that “we believe” and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based on information available to us as of the date of this prospectus. While we believe that such information provides a reasonable basis for these statements, such information may be limited or incomplete. Our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all relevant information. These statements are inherently uncertain, and investors are cautioned not to unduly rely on these statements.
All subsequent written or oral forward-looking statements attributable to us or any person acting on our behalf are expressly qualified in their entirety by the cautionary statements contained or referred to in this section. We do not undertake any obligation to release publicly any revisions to these forward-looking statements to reflect events or circumstances after the date of this prospectus or to reflect the occurrence of unanticipated events, except as may be required under applicable U.S. securities laws. If we do update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements.
| 2 |
This summary may not contain all the information that you should consider before investing in securities. You should read the entire prospectus and the information incorporated by reference in this prospectus carefully, including “Risk Factors” and the financial data and related notes and other information incorporated by reference herein, before making an investment decision.
Company Overview
We are a commercial-stage biopharmaceutical company building a portfolio of therapies for rare and serious diseases with multiple opportunities for value creation. The Company’s portfolio includes ZEVASKYN® (prademagene zamikeracel), the first and only autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa; ABO-801, a Phase 3-ready product candidate for eosinophilic esophagitis; and ABO-701 (PSMA-SIR-T™), an investigational engineered T-cell therapy targeting PSMA.
ZEVASKYN® is manufactured at our cGMP manufacturing facility in Cleveland, Ohio. Treatments are available through ZEVASKYN® qualified treatment centers, a network of centers that are selected based on their expertise in cell and gene therapy and trained to administer ZEVASKYN®. As of November 2026, we have activated eight qualified treatment centers and are in discussions with additional centers as we continue to expand the ZEVASKYN® qualified treatment network.
On November 6, 2026, we acquired APT-1011, now ABO-801, from Ellodi Pharmaceuticals. ABO-801 is a Phase 3-ready, once-daily oral disintegrating tablet formulation of fluticasone propionate in development for eosinophilic esophagitis (“EoE”). APT-1011 is an orally disintegrating tablet formulation containing fluticasone propionate as the active pharmaceutical ingredient, designed to treat EoE. EoE is a chronic, progressive allergic disease that can lead to strictures and food impaction.
| 3 |
Recent Developments
The Acquisition
On November 6, 2026, we completed the Acquisition of ABO-801 from Ellodi Pharmaceuticals in accordance with the terms of the Asset Purchase Agreement, pursuant to which we acquired certain assets relating to APT-1011 from Ellodi Pharmaceuticals. Upfront consideration for the acquisition consisted of 4,494,383 shares of our Common Stock. No upfront cash consideration was paid. Ellodi Pharmaceuticals is also eligible to receive $30 million upon U.S. Food and Drug Administration (“FDA”) approval of ABO-801, up to an additional $30 million upon achievement of specified sales milestones, and tiered royalties on net sales ranging from low to mid teen percentages. The closing of the Acquisition was not subject to the approval of our stockholders.
Private Placement
Concurrently with the Acquisition, we entered into the Securities Purchase Agreement with the Investors, pursuant to which, on November 11, 2026, we issued and sold an aggregate of 6,400,000 shares of Common Stock at a price of $3.75 per share and Pre-Funded Warrants to purchase 1,600,043 shares of Common Stock at a price of $3.7499 per Pre-Funded Warrant, for aggregate gross proceeds of approximately $30 million.
On November 6, 2026, we entered into a registration rights agreement with Ellodi Pharmaceuticals (the “Ellodi Registration Rights Agreement”), and on November 11, 2026, we entered into a registration rights agreement with the Investors (the “Private Placement Registration Rights Agreement”, and collectively, the “Registration Rights Agreements”). Pursuant to the Ellodi Registration Rights Agreement, we are obligated to prepare and file a resale registration statement with the SEC within 14 calendar days following the closing of the Acquisition. Pursuant to the Private Placement Registration Rights Agreement, we are obligated to prepare and file a resale registration statement with the SEC within 15 calendar days following the closing of the Private Placement. The Registration Rights Agreements also contain customary terms, including an obligation to indemnify Ellodi Pharmaceuticals and the Investors and certain of their respective affiliates from certain liabilities relating to any misstatements or omissions in the resale registration statement.
Pursuant to the Asset Purchase Agreement, the Acquisition Shares are subject to a lockup on the sale or transfer, subject to certain limited exceptions as set forth in the Asset Purchase Agreement. Pursuant to the Asset Purchase Agreement, the Acquisition Shares will be released from the lockup in one-third increments on each of the six-month, 12-month, and 18-month anniversaries of the Acquisition closing date, provided that 337,079 of the shares allocated to the one-third portion subject to the six-month lockup are not subject to the contractual lockup, but remain subject to applicable securities laws. Upon the 18-month anniversary of the Acquisition closing date, all of the Acquisition Shares will be released from the contractual lockup, subject to applicable securities laws.
Corporate Information
We were incorporated in 1974. On October 24, 2014, we changed our name to PlasmaTech Biopharmaceuticals, Inc., and on June 19, 2015, we changed our name to Abeona Therapeutics Inc. to reflect our broader rare disease commitment. Our principal executive office is located at 6555 Carnegie Avenue, 4th Floor Cleveland, OH 44103, and our telephone number is (646) 813-4701. Our website address is www.abeonatherapeutics.com. We do not incorporate by reference into this registration statement or prospectus the information on our website, and you should not consider it as part of this registration statement or prospectus.
Implications of Being a Smaller Reporting Company
We
are a “smaller reporting company” as defined in the Exchange Act. We may take advantage of certain of the scaled disclosures
available to smaller reporting companies, including reduced disclosure obligations regarding executive compensation. As a non-accelerated
filer, we are not required to comply with the auditor attestation requirements of Section 404(b) of the Sarbanes-Oxley Act of 2002. We
will be able to take advantage of these scaled disclosures for so long as the market value of our Common Stock held by non-affiliates
is less than $250 million measured on the last business day of our second fiscal quarter, or our annual revenue is less than $100 million
during the most recently completed fiscal year and the market value of our Common Stock held by non-affiliates is less than $700 million
measured on the last business day of our second fiscal quarter. As a result, the information in or incorporated by reference into this
prospectus and that we provide to our investors in the future may be different than what you might receive from other public reporting
companies.
| 4 |
THE OFFERING
Common stock offered by the Selling Stockholders |
12,494,426 shares of Common Stock, which consist of (i) 4,494,383 Acquisition Shares, (ii) 6,400,000 Private Placement Shares, and (iii) 1,600,043 Pre-Funded Warrant Shares. | |
| Terms of the offering | Each Selling Stockholder will determine when and how it will sell the common stock offered in this prospectus, as described in “Plan of Distribution.” | |
| Use of proceeds | We will not receive any proceeds from the sale of the Acquisition Shares or the Private Placement Shares. We would receive approximately $160 in aggregate exercise proceeds if all Pre-Funded Warrants were exercised for cash when permitted, and no exercise proceeds from cashless exercises. | |
Risk factors |
See “Risk Factors” on page 6 for a discussion of factors you should carefully consider before deciding to invest in our Common Stock. | |
| Nasdaq Capital Market symbol: | “ABEO” |
| 5 |
Investing in shares of our Common Stock involves a high degree of risk. Before deciding whether to invest in shares of our Common Stock, you should consider carefully the risks and uncertainties discussed in this section and under the sections titled Risk Factors contained in our most recent Annual Report on Form 10-K and in our most recent Quarterly Report on Form 10-Q, as well as any amendments thereto reflected in subsequent filings with the SEC, which are incorporated by reference into this prospectus in their entirety, together with other information in this prospectus, the documents incorporated by reference, any prospectus supplement and any free writing prospectus that we may authorize. Please also read carefully the section titled “Cautionary Statement Regarding Forward-Looking Statements.”
| 6 |
We are not selling any securities under this prospectus and we will not receive any proceeds from the sale of the Resale Shares covered hereby. The net proceeds from the sale of the Resale Shares offered by this prospectus will be received by the Selling Stockholders. The Pre-Funded Warrants have an exercise price of $0.0001 per share and permit cashless exercise. Under their terms, if a registration statement registering the issuance of the underlying shares is not effective at the time of exercise, the Pre-Funded Warrants may be exercised only on a cashless basis. This prospectus registers resales, not the issuance of the underlying shares. We would receive approximately $160 in aggregate exercise proceeds if all Pre-Funded Warrants were exercised for cash when permitted, and no exercise proceeds from cashless exercises.
Subject to limited exceptions, the Selling Stockholders will pay any underwriting discounts and commissions and expenses incurred by the Selling Stockholders for brokerage, accounting, tax or legal services or any other expenses incurred by the Selling Stockholders in disposing of any of the Resale Shares. We will bear the costs, fees and expenses incurred in effecting the registration of the Resale Shares covered by this prospectus, including all registration and filing fees, Nasdaq listing fees and fees and expenses of our counsel and our independent registered public accounting firm.
| 7 |
This prospectus covers the resale or other disposition from time to time by the Selling Stockholders identified in the table below of up to an aggregate of 12,494,426 shares of Common Stock, which consist of (i) 4,494,383 Acquisition Shares, (ii) 6,400,000 Private Placement Shares and (iii) 1,600,043 Pre-Funded Warrant Shares. The Selling Stockholders may from time to time offer and sell any or all of the Resale Shares set forth below pursuant to this prospectus and any accompanying prospectus supplement.
On November 6, 2026, we completed the Acquisition in accordance with the Asset Purchase Agreement, pursuant to which we issued an aggregate of 4,494,383 shares of Common Stock. Also on November 6, 2026, we entered into the Securities Purchase Agreement, pursuant to which, on November 11, 2026, we issued and sold an aggregate of 6,400,000 shares and Pre-Funded Warrants to purchase 1,600,043 shares, at an aggregate purchase price of approximately $30 million.
We are registering the Resale Shares to permit the Selling Stockholders and their pledgees, donees, transferees or other successors-in-interest that receive their shares after the date of this prospectus to resell or otherwise dispose of the shares in the manner contemplated under “Plan of Distribution” herein.
Except as otherwise disclosed herein, the Selling Stockholders do not have, and within the past three years have not had, any material position, office or other material relationship with us.
The following table sets forth the names of the Selling Stockholders, the number of shares of our Common Stock owned by the Selling Stockholders, the number of shares of our Common Stock that may be offered under this prospectus and the number of shares of our Common Stock that will be owned after this offering by the Selling Stockholders assuming all of the shares registered for resale hereby are sold.
The Selling Stockholders may sell some, all or none of their Resale Shares. We do not know how long the Selling Stockholders will hold the Resale Shares before selling them, and we currently have no agreements, arrangements or understandings with the Selling Stockholders regarding the sale or other disposition of any of the Resale Shares, except for the lockup provisions in the Asset Purchase Agreement regarding the Acquisition Shares. The Resale Shares covered hereby may be offered from time to time by the Selling Stockholders.
The information set forth below is based upon information obtained from the Selling Stockholders. The percentages of Common Stock owned after the offering by each Selling Stockholder below are based on 68,307,890 shares of Common Stock outstanding as of November 12, 2026.
| Name of Selling Stockholders(1) | Common Stock
Beneficially Owned
Before Offering(2) | Common Stock that
May Be Offered
Pursuant to
Prospectus(2) | Common Stock Beneficially
Owned | |||||||||||||
| Number | Percentage
(%) | |||||||||||||||
| Blackwell Partners LLC - Series A (3) | 7,112,428 | 152,269 | 6,960,159 | 10.2 | ||||||||||||
| Eastmain 2023 Fund LP (4) | 974,605 | 698,944 | 275,661 | * | ||||||||||||
| Ellodi Pharmaceuticals, L.P. (5) | 4,494,383 | 4,494,383 | — | * | ||||||||||||
| Ghisallo Master Fund LP (6) | 660,000 | 660,000 | — | * | ||||||||||||
| Entities associated with Great Point Partners LLC (7) | 666,666 | 666,666 | — | * | ||||||||||||
| Marshall Wace Investment Strategies - Eureka Fund (8) | 266,667 | 266,667 | — | * | ||||||||||||
| Entities associated with Monashee Investment Management LLC (9) | 660,000 | 660,000 | — | * | ||||||||||||
| Nantahala Capital Partners Limited Partnership (10) | 4,484,567 | 549,763 | 3,934,804 | 5.8 | % | |||||||||||
| NCP RFM LP (11) | 2,165,925 | 199,067 | 1,966,858 | 2.9 | % | |||||||||||
| Perceptive Life Sciences Master Fund, Ltd. (12) | 2,000,000 | 2,000,000 | — | * | ||||||||||||
| TPG LSI Rise Ellodi, L.P. (13) | 266,667 | 266,667 | — | * | ||||||||||||
| Woodline Master Fund LP (14) | 1,880,000 | 1,880,000 | — | * | ||||||||||||
| * | Less than 1% |
| (1) | “Beneficial ownership” means that a person, directly or indirectly, has or shares voting or investment power with respect to a security or has the right to acquire such power within 60 days. |
| 8 |
| (2) | Assumes exercise of all Pre-Funded Warrants and sale of all shares of Common Stock covered by this prospectus, and no further acquisitions of shares of Common Stock by the Selling Stockholders other than upon such exercise. |
| (3) | “Common Stock that May Be Offered Pursuant to Prospectus” consists of 152,269 shares issuable upon the exercise of Pre-Funded Warrants held by Blackwell Partners LLC - Series A (“Blackwell”). “Common Stock Beneficially Owned Before Offering” also includes 864,701 shares held by Blackwell and 6,095,458 shares issuable upon the exercise of warrants that are not being offered by this prospectus. Nantahala Capital Management, LLC is a Registered Investment Adviser and has been delegated the legal power to vote and/or direct the disposition of such securities on behalf of Blackwell as a General Partner, Investment Manager, or Sub-Advisor and may be deemed to be the beneficial owner of shares held by Blackwell, subject to the beneficial ownership limitations described below. Wilmot Harkey and Daniel Mack are managing members of Nantahala Capital Management, LLC and may be deemed to have voting and dispositive power over the shares held by Blackwell, subject to the beneficial ownership limitations described below. The address of Nantahala Capital Management, LLC is 130 Main Street, 2nd Floor, New Canaan, CT 06840. The Pre-Funded Warrants held by Blackwell prohibit the exercise thereof if, after giving effect to such exercise, the beneficial ownership of the holder and its affiliates and any person whose beneficial ownership would be attributable to such entity, would exceed 9.99%. The holder may increase this limitation to no more than 19.99% on 61 days’ prior notice. The number of shares registered for resale is not reduced by this limitation. |
| (4) | “Common Stock that May Be Offered Pursuant to Prospectus” consists of 698,944 shares issuable upon the exercise of Pre-Funded Warrants held by Eastmain 2023 Fund LP (“Eastmain”). “Common Stock Beneficially Owned Before Offering” also includes 275,661 shares held by Eastmain that are not being offered by this prospectus. Nantahala Capital Management, LLC is a Registered Investment Adviser and has been delegated the legal power to vote and/or direct the disposition of such securities on behalf of Eastmain as a General Partner, Investment Manager, or Sub-Advisor and may be deemed to be the beneficial owner of shares held by Eastmain, subject to the beneficial ownership limitations described below. Wilmot Harkey and Daniel Mack are managing members of Nantahala Capital Management, LLC and may be deemed to have voting and dispositive power over the shares held by Eastmain, subject to the beneficial ownership limitations described below. The address of Nantahala Capital Management, LLC is 130 Main Street, 2nd Floor, New Canaan, CT 06840. The Pre-Funded Warrants held by Eastmain prohibit the exercise thereof if, after giving effect to such exercise, the beneficial ownership of the holder and its affiliates and any person whose beneficial ownership would be attributable to such entity, would exceed 9.99%. The holder may increase this limitation to no more than 19.99% on 61 days’ prior notice. The number of shares registered for resale is not reduced by this limitation. |
| (5) | Represents 4,494,383 shares held by Ellodi Pharmaceuticals, L.P., a Delaware limited partnership (“Ellodi Pharmaceuticals”). The general partner of Ellodi Pharmaceuticals is Ellodi Development I GenPar, LLC, a Delaware limited liability company, whose sole member is Ellodi Pharmaceuticals Holdings, L.P., a Cayman Islands limited partnership, whose general partner is Ellodi Pharmaceuticals Holdings GenPar, Ltd., a Cayman Islands company, whose sole shareholder is TPG Valley, L.P., a Cayman Islands limited partnership, whose general partner is Valley Holdings GP, LLC, a Cayman Islands limited liability company, whose controlling member is TPG Valley Aggregation, L.P., a Cayman Islands limited partnership, whose general partner is TPG GenPar VI-AIV, L.P., a Cayman Islands limited partnership, whose general partner is TPG GenPar VI-AIV Advisors, Inc., a Cayman Islands exempted company, whose sole shareholder is TPG Operating Group III, L.P., a Delaware limited partnership, whose general partner is TPG Holdings III-A, L.P., a Cayman Islands limited partnership, whose general partner is TPG Holdings III-A, LLC, a Cayman Islands limited liability company, whose sole member is TPG Operating Group II, L.P., a Delaware limited partnership, whose general partner is TPG Holdings II-A, LLC, a Delaware limited liability company, whose sole member is TPG GPCo, LLC, a Delaware limited liability company, whose sole member is TPG Inc., a Delaware corporation, whose shares of Class B common stock (which represent a majority of the combined voting power of the common stock) are collectively held by entities over which TPG GP A, LLC, a Delaware limited liability company, exercises direct or indirect control. TPG GP A, LLC is controlled by entities owned by James G. Coulter and Jon Winkelried. Because of the relationship of Messrs. Coulter and Winkelried to TPG GP A, LLC, each of Messrs. Coulter and Winkelried may be deemed to beneficially own the securities held by Ellodi Pharmaceuticals. Messrs. Coulter and Winkelried disclaim beneficial ownership of the securities held by Ellodi Pharmaceuticals except to the extent of their pecuniary interest therein, if any. The address of TPG GP A, LLC and each of Messrs. Coulter and Winkelried is c/o TPG Inc., 301 Commerce Street, Suite 3300, Fort Worth, TX 76102. |
| (6) | Ghisallo Capital Management LLC (“Ghisallo Capital”) is the investment manager of the selling stockholder. Ghisallo Capital and Michael Germino, who indirectly controls Ghisallo Capital, have shared voting and investment power over the shares. The shares held by the selling stockholder may be deemed to be beneficially owned by Ghisallo Capital and Mr. Germino. Notwithstanding the foregoing, Mr. Germino disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein. The address for the selling stockholder is 190 Elgin Avenue, George Town Grand Cayman, CI KY1-9008. |
| 9 |
| (7) | Consists of (i) 440,000 shares held by Biomedical Value Fund, L.P. (“BVF”), and (ii) 226,666 shares held by Biomedical Offshore Value Fund, Ltd. (“BOVF”). Great Point Partners, LLC (“Great Point”) is the investment manager of each of BVF and BOVF, and by virtue of such status may be deemed to be the beneficial owner of the shares held by each of BVF and BOVF. Each of Dr. Jeffrey R. Jay, M.D., as Senior Managing Member of Great Point, and Ms. Lillian Nordahl, as Managing Director of Great Point, has voting and investment power with respect to the shares held by the BVF and BOVF, and therefore may be deemed to be the beneficial owner of such shares. Notwithstanding the above, each of Great Point, Dr. Jay and Ms. Nordahl disclaims beneficial ownership of the shares held by each of BVF and BOVF, except to the extent of their respective pecuniary interests. The address of each of the individuals and entities referenced in this footnote is 165 Mason Street, 3rd Floor, Greenwich, CT 06830. |
| (8) | Marshall Wace LLP is the investment manager to the selling stockholder. The address of the foregoing entities is George House, 131 Sloane Street, London, SW1X 9AT, United Kingdom. |
| (9) | Represents (i) 290,911 shares held by HIF Solitude Ltd (“HIF”) and (ii) 369,089 shares held by Mission Pure Alpha Master LP (“MPAM”). MPAM and HIF are managed by Monashee Investment Management, LLC (“Monashee Management”). Jeff Muller is CCO of Monashee Management and has voting and investment control over Monashee Management and, accordingly, may be deemed to have beneficial ownership of the shares held by MPAM and HIF. Mr. Muller, however, disclaims any beneficial ownership of the shares held by these entities. The business address of MPAM and HIF and Mr. Muller is c/o Monashee Investment Management, LLC, 75 Park Plaza, 4th Floor, Boston, Massachusetts 02116. |
| (10) | “Common Stock that May Be Offered Pursuant to Prospectus” consists of 549,763 shares issuable upon the exercise of Pre-Funded Warrants held by Nantahala Capital Partners Limited Partnership (“NCPLP”). “Common Stock Beneficially Owned Before Offering” also includes 3,353,584 shares held by NCPLP and 581,220 shares issuable upon the exercise of warrants that are not being offered by this prospectus. Nantahala Capital Management, LLC is a Registered Investment Adviser and has been delegated the legal power to vote and/or direct the disposition of such securities on behalf of NCPLP as a General Partner, Investment Manager, or Sub-Advisor and may be deemed to be the beneficial owner of shares held by NCPLP, subject to the beneficial ownership limitations described below. Wilmot Harkey and Daniel Mack are managing members of Nantahala Capital Management, LLC and may be deemed to have voting and dispositive power over the shares held by NCPLP, subject to the beneficial ownership limitations described below. The address of Nantahala Capital Management, LLC is 130 Main Street, 2nd Floor, New Canaan, CT 06840. The Pre-Funded Warrants held by NCPLP prohibit the exercise thereof if, after giving effect to such exercise, the beneficial ownership of the holder and its affiliates and any person whose beneficial ownership would be attributable to such entity, would exceed 9.99%. The holder may increase this limitation to no more than 19.99% on 61 days’ prior notice. The number of shares registered for resale is not reduced by this limitation. |
| (11) | “Common Stock that May Be Offered Pursuant to Prospectus” consists of 199,067 shares issuable upon the exercise of Pre-Funded Warrants held by NCP RFM LP (“NCP RFM”). “Common Stock Beneficially Owned Before Offering” also includes 618,959 shares held by NCP RFM and 1,347,899 shares issuable upon the exercise of warrants that are not being offered by this prospectus. Nantahala Capital Management, LLC is a Registered Investment Adviser and has been delegated the legal power to vote and/or direct the disposition of such securities on behalf of NCP RFM as a General Partner, Investment Manager, or Sub-Advisor and may be deemed to be the beneficial owner of shares held by NCP RFM, subject to the beneficial ownership limitations described below. Wilmot Harkey and Daniel Mack are managing members of Nantahala Capital Management, LLC and may be deemed to have voting and dispositive power over the shares held by NCP RFM, subject to the beneficial ownership limitations described below. The address of Nantahala Capital Management, LLC is 130 Main Street, 2nd Floor, New Canaan, CT 06840. The Pre-Funded Warrants held by NCP RFM prohibit the exercise thereof if, after giving effect to such exercise, the beneficial ownership of the holder and its affiliates and any person whose beneficial ownership would be attributable to such entity, would exceed 9.99%. The holder may increase this limitation to no more than 19.99% on 61 days’ prior notice. The number of shares registered for resale is not reduced by this limitation. |
| (12) | Perceptive Advisors LLC (“Perceptive Advisors”) is the investment advisor to Perceptive Life Sciences Master Fund, Ltd. (the “Perceptive Master Fund”) and may be deemed to have beneficial ownership of the shares beneficially owned thereby. Joseph Edelman is the controlling person of Perceptive Advisors and accordingly may be deemed to have beneficial ownership of the shares beneficially owned by the Perceptive Master Fund and Perceptive Advisors. Perceptive Advisors, the Perceptive Master Fund, and Mr. Edelman disclaim beneficial ownership of all such shares, except to the extent of any pecuniary interest therein. The principal business address of Perceptive Advisors, the Perceptive Master Fund and Mr. Edelman is 51 Astor Place, 10th Floor, New York, NY 10003. |
| (13) | Represents 266,667 shares held by TPG LSI Rise Ellodi, L.P., a Delaware limited partnership. The general partner of TPG LSI Rise Ellodi, L.P. is TPG LSI SPV GP, LLC, a Delaware limited liability company, whose sole member is TPG LSI GenPar, L.P., a Delaware limited partnership, whose general partner is TPG LSI GenPar Advisors, LLC, a Delaware limited liability company, whose sole member is TPG Operating Group I, L.P., a Delaware limited partnership, whose general partner is TPG Holdings I-A, LLC, a Delaware limited liability company, whose sole member is TPG Operating Group II, L.P., a Delaware limited partnership, whose general partner is TPG Holdings II-A, LLC, a Delaware limited liability company, whose sole member is TPG GPCo, LLC, a Delaware limited liability company, whose sole member is TPG Inc., a Delaware corporation, whose shares of Class B common stock (which represent a majority of the combined voting power of the common stock) are collectively held by entities over which TPG GP A, LLC, a Delaware limited liability company, exercises direct or indirect control. TPG GP A, LLC is controlled by entities owned by James G. Coulter and Jon Winkelried. Because of the relationship of Messrs. Coulter and Winkelried to TPG GP A, LLC, each of Messrs. Coulter and Winkelried may be deemed to beneficially own the securities held by TPG LSI Rise Ellodi, L.P. Messrs. Coulter and Winkelried disclaim beneficial ownership of the securities held by TPG LSI Rise Ellodi, L.P. except to the extent of their pecuniary interest therein, if any. The address of TPG GP A, LLC and each of Messrs. Coulter and Winkelried is c/o TPG Inc., 301 Commerce Street, Suite 3300, Fort Worth, TX 76102. |
| (14) | Woodline Partners LP serves as the investment manager of Woodline Master Fund LP (the “Fund”) and may be deemed to be the beneficial owner of the shares of Common Stock. Woodline Partners LP disclaims any beneficial ownership of these shares. The address of the Fund is 4 Embarcadero Center, Suite 3450, San Francisco, CA 94111. |
Acquisition
See the section titled “Prospectus Summary—Recent Developments” for a description of the terms of the agreements entered into in connection with the Acquisition, which is incorporated herein by reference.
| 10 |
The selling stockholders, which, as used herein includes donees, pledgees, transferees or other successors-in-interest selling shares of common stock or interests in shares of common stock received after the date of this prospectus from a selling stockholder as a gift, pledge, partnership distribution or other transfer, may, from time to time, sell, transfer or otherwise dispose of any or all of their shares of common stock or interests in shares of common stock on any stock exchange, market or trading facility on which the shares are traded or in private transactions. These dispositions may be at fixed prices, at prevailing market prices at the time of sale, at prices related to the prevailing market price, at varying prices determined at the time of sale, or at negotiated prices.
The selling stockholders may use any one or more of the following methods when disposing of shares or interests therein:
| ● | distributions to members, partners, stockholders or other equityholders of the selling stockholders; |
| ● | ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers; |
| ● | block trades in which the broker-dealer will attempt to sell the shares as agent, but may position and resell a portion of the block as principal to facilitate the transaction; |
| ● | purchases by a broker-dealer as principal and resale by the broker-dealer for its account; |
| ● | an exchange distribution in accordance with the rules of the applicable exchange; |
| ● | privately negotiated transactions; |
| ● | short sales and settlement of short sales entered into after the effective date of the registration statement of which this prospectus is a part; |
| ● | through the writing or settlement of options or other hedging transactions, whether through an options exchange or otherwise; |
| ● | broker-dealers may agree with the selling stockholders to sell a specified number of such shares at a stipulated price per share; |
| ● | a combination of any such methods of sale; and |
| ● | any other method permitted pursuant to applicable law. |
The selling stockholders may, from time to time, pledge or grant a security interest in some or all of the shares of common stock owned by them and, if they default in the performance of their secured obligations, the pledgees or secured parties may offer and sell the shares of common stock, from time to time, under this prospectus, or under an amendment to this prospectus under Rule 424(b)(3) or other applicable provision of the Securities Act, amending the list of selling stockholders to include the pledgee, transferee or other successors-in-interest as selling stockholders under this prospectus. The selling stockholders also may transfer the shares of common stock in other circumstances, in which case the transferees, pledgees or other successors-in-interest will be the selling stockholders for purposes of this prospectus.
In connection with the sale of our common stock or interests therein, the selling stockholders may enter into hedging transactions with broker-dealers or other financial institutions, which may in turn engage in short sales of the common stock in the course of hedging the positions they assume. The selling stockholders may also sell shares of our common stock short and deliver these securities to close out their short positions, or loan or pledge the common stock to broker-dealers that in turn may sell these securities. The selling stockholders may also enter into option or other transactions with broker-dealers or other financial institutions or the creation of one or more derivative securities which require the delivery to such broker-dealer or other financial institution of shares offered by this prospectus, which shares such broker-dealer or other financial institution may resell pursuant to this prospectus (as supplemented or amended to reflect such transaction).
| 11 |
The aggregate proceeds to the selling stockholders from the sale of the common stock offered by them will be the purchase price of the common stock less discounts or commissions, if any. Each of the selling stockholders reserves the right to accept and, together with their agents from time to time, to reject, in whole or in part, any proposed purchase of common stock to be made directly or through agents. We will not receive any of the proceeds from this offering.
The selling stockholders also may resell all or a portion of the shares in open market transactions in reliance upon Rule 144 under the Securities Act, provided that they meet the criteria and conform to the requirements of that rule, or another available exemption from the registration requirements under the Securities Act.
The selling stockholders and any underwriters, broker-dealers or agents that participate in the sale of the common stock or interests therein may be “underwriters” within the meaning of Section 2(a)(11) of the Securities Act. Any discounts, commissions, concessions or profit they earn on any resale of the shares may be underwriting discounts and commissions under the Securities Act. Selling stockholders who are “underwriters” within the meaning of Section 2(a)(11) of the Securities Act will be subject to the prospectus delivery requirements of the Securities Act.
To the extent required, the shares of our common stock to be sold, the names of the selling stockholders, the respective purchase prices and public offering prices, the names of any agent, dealer or underwriter, and any applicable commissions or discounts with respect to a particular offer will be set forth in an accompanying prospectus supplement or, if appropriate, a post-effective amendment to the registration statement that includes this prospectus.
To comply with the securities laws of some states, if applicable, the common stock may be sold in these jurisdictions only through registered or licensed brokers or dealers. In addition, in some states the common stock may not be sold unless it has been registered or qualified for sale or an exemption from registration or qualification requirements is available and is complied with.
We have advised the selling stockholders that the anti-manipulation rules of Regulation M under the Exchange Act may apply to sales of shares in the market and to the activities of the selling stockholders and their affiliates. In addition, to the extent applicable, we will make copies of this prospectus (as it may be supplemented or amended from time to time) available to the selling stockholders for the purpose of satisfying the prospectus delivery requirements of the Securities Act. The selling stockholders may indemnify any broker-dealer that participates in transactions involving the sale of the shares against certain liabilities, including liabilities arising under the Securities Act.
We have agreed to indemnify the selling stockholders against liabilities, including liabilities under the Securities Act and state securities laws, relating to the registration of the shares offered by this prospectus.
We have agreed with Ellodi Pharmaceuticals to use reasonable best efforts to cause the registration statement of which this prospectus constitutes a part to become effective and remain continuously effective until the earlier of (i) the resale of all securities covered thereby, excluding permitted assignments under the Ellodi Registration Rights Agreement, and (ii) the date those securities may be resold without registration and without volume, manner-of-sale, or current-public-information requirements under Rule 144 or a rule of similar effect. Registration does not release any applicable contractual lockup restrictions; permitted distributions remain subject to the transferee’s assumption of the applicable remaining restrictions.
We have agreed with the Investors to use reasonable best efforts to cause the registration statement of which this prospectus constitutes a part to become effective and remain continuously effective until the earlier of: (i) the date on which the selling stockholders shall have resold or otherwise disposed of all the shares covered by this prospectus and (ii) the date on which the shares covered by this prospectus no longer constitute “Registrable Securities” as such term is defined in the Private Placement Registration Rights Agreement, such that they may be resold by the selling stockholders without registration and without regard to any volume or manner-of-sale limitations and without current public information pursuant to Rule 144 under the Securities Act or any other rule of similar effect.
There can be no assurance that any Selling Stockholder will sell any or all of the Resale Shares registered pursuant to the registration statement of which this prospectus forms a part.
| 12 |
Certain legal matters, including the legality of the securities offered, will be passed upon for us by Carlton Fields, P.A., Tampa, FL. Additional legal matters may be passed upon for us or any underwriters, dealers or agents, by counsel that we will name in the applicable prospectus supplement.
The financial statements of Abeona Therapeutics Inc. incorporated by reference in this Prospectus, have been audited by Deloitte & Touche LLP, an independent registered public accounting firm, as stated in their report. Such financial statements are incorporated by reference in reliance upon the report of such firm, given their authority as experts in accounting and auditing.
DISCLOSURE OF COMMISSION POSITION ON INDEMNIFICATION FOR SECURITIES ACT LIABILITIES
We provide indemnification to our directors and officers under our certificate of incorporation, bylaws and indemnification agreements, subject to applicable law. Insofar as indemnification for liabilities arising under the Securities Act may be permitted to our directors, officers and controlling persons pursuant to those provisions, or otherwise, we have been advised that, in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable.
WHERE YOU CAN FIND MORE INFORMATION
We are subject to the informational requirements of the Exchange Act and are required to file annual, quarterly and other reports, proxy statements and other information with the SEC. The SEC maintains an internet site (www.sec.gov) that contains reports, proxy and information statements, and various other information about us.
Information about us is also available at our website at www.abeonatherapeutics.com. However, the information on, or that can be accessed through, our website is not a part of this prospectus and is not incorporated by reference into this prospectus.
INCORPORATION OF INFORMATION BY REFERENCE
The SEC allows us to “incorporate by reference” information that we file with the SEC, which means that we can disclose important information to you by referring you to those other documents. The information incorporated by reference is an important part of this prospectus, and information we file later with the SEC will automatically update and supersede this information. A Current Report (or portion thereof) furnished, but not filed, on Form 8-K shall not be incorporated by reference into this prospectus. We incorporate by reference the documents listed below and any future filings we make with the SEC under Section 13(a), 13(c), 14, or 15(d) of the Exchange Act, including all filings made after the date of the filing of this registration statement and prior to the effectiveness of this registration statement, except, in each case, as to any portion of any future report or document that is not deemed filed under such provisions, prior to the termination of any offering of securities made by this prospectus:
| ● | our Annual Report on Form 10-K for the fiscal year ended December 31, 2025 (filed with the SEC on March 17, 2026); |
| ● | our Quarterly Reports on Form 10-Q for the fiscal quarters ended March 31, 2026, June 30, 2026, and September 30, 2026 (filed with the SEC on May 13, 2026, August 13, 2026, and November 9, 2026, respectively); |
| ● | our Current Reports on Form 8-K filed with the SEC on March 9, 2026, March 20, 2026, April 7, 2026, June 4, 2026, June 12, 2026, June 12, 2026, and November 9, 2026; and |
| ● | the description of our common stock, par value $0.01 per share contained in our Registration Statement on Form 8-A, dated and filed with the SEC on November 4, 2014, as updated by Exhibit 4.4 to our Form 10-K for the fiscal year ended December 31, 2019, and including any amendments or reports filed with the SEC for the purpose of updating such description. |
We will furnish without charge to you, on written or oral request, a copy of any or all of such documents that has been incorporated herein by reference (other than exhibits to such documents unless such exhibits are specifically incorporated by reference into the documents that this prospectus incorporates). Written or oral requests for copies should be directed to Abeona Therapeutics Inc., Attn: Corporate Secretary, 6555 Carnegie Ave, 4th Floor, Cleveland, OH 44103, telephone number (646) 813-4701. See the section of this prospectus entitled “Where You Can Find More Information” for information concerning how to read and obtain copies of materials that we file with the SEC.
Any statement contained in this prospectus, or in a document all or a portion of which is incorporated by reference, shall be modified or superseded for purposes of this prospectus to the extent that a statement contained in this prospectus, any prospectus supplement or any document incorporated by reference modifies or supersedes such statement. Any such statement so modified or superseded shall not, except as so modified or superseded, constitute a part of this prospectus.
| 13 |
PART II
INFORMATION NOT REQUIRED IN PROSPECTUS
| Item 14. | Other Expenses of Issuance and Distribution |
The expenses payable by us in connection with the issuance and distribution of the securities being registered hereunder on Form S-3 (other than underwriting discounts and commissions, if any) are set forth below. The Selling Stockholders will not bear any portion of such expenses. Each item listed is estimated, except for the SEC registration fee:
| SEC registration fee | $ | 2,467.52 | ||
| Legal fees and expenses | 20,000 | |||
| Accounting fees and expenses | 60,000 | |||
| Total | $ | 82,467.52 |
| Item 15. | Indemnification of Officers and Directors |
Section 145 of the General Corporation Law of Delaware (“DGCL”) empowers a Delaware corporation to indemnify its officers and directors and certain other persons to the extent and under the circumstances set forth therein.
We have entered into indemnification agreements with each of our current directors and executive officers. These agreements require us to indemnify these individuals to the fullest extent permitted under Delaware law against liabilities that may arise by reason of their service to us, and to advance expenses incurred as a result of any proceeding against them as to which they could be indemnified.
Our certificate of incorporation and bylaws provide for indemnification of our officers and directors and certain other persons against liabilities and expenses incurred by any of them in certain stated proceedings and under certain stated conditions.
The above discussion of our certificate of incorporation, as amended, bylaws and Section 145 of DGCL is not intended to be exhaustive and is qualified in its entirety by such certificate of incorporation, bylaws, and statute.
We maintain a liability insurance policy that covers certain liabilities of our directors and officers arising out of claims based on acts or omissions in their capacities as directors or officers.
| II-1 |
| Item 16. | Exhibits |
| * | Filed herewith. | |
| † | Portions of this exhibit have been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K. | |
| ** | Certain schedules, annexes and attachments have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Registrant agrees to furnish supplementally a copy of any omitted schedule, annex or attachment to the SEC upon request. |
| Item 17. | Undertakings |
| (a) | The undersigned Registrant hereby undertakes: |
| (1) | To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement: |
| (i) | to include any prospectus required by Section 10(a)(3) of the Securities Act; |
| (ii) | to reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the SEC pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20 percent change in the maximum aggregate offering price set forth in the “Filing Fee Table” in the effective registration statement; and |
| (iii) | to include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement; |
provided, however, that subparagraphs (i),(ii), and (iii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the SEC by the Registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in the registration statement, or is contained in a form of prospectus filed pursuant to Rule 424(b) that is part of the registration statement.
| II-2 |
| (2) | That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. |
| (3) | To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering. |
| (4) | That, for the purpose of determining liability under the Securities Act to any purchaser: |
| (i) | Each prospectus filed by the Registrant pursuant to Rule 424(b)(3) shall be deemed to be part of the registration statement as of the date the filed prospectus was deemed part of and included in the registration statement; and |
| (ii) | Each prospectus required to be filed pursuant to Rule 424(b)(2), (b)(5), or (b)(7) as part of a registration statement in reliance on Rule 430B relating to an offering made pursuant to Rule 415(a)(1)(i), (vii), or (x) for the purpose of providing the information required by Section 10(a) of the Securities Act shall be deemed to be part of and included in the registration statement as of the earlier of the date such form of prospectus is first used after effectiveness or the date of the first contract of sale of securities in the offering described in the prospectus. As provided in Rule 430B, for liability purposes of the issuer and any person that is at that date an underwriter, such date shall be deemed to be a new effective date of the registration statement relating to the securities in the registration statement to which that prospectus relates, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. Provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such effective date, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such effective date. |
| (b) | That, for purposes of determining any liability under the Securities Act, each filing of the Registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. |
| (c) | Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers, and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer, or controlling person of the Registrant in the successful defense of any action, suit, or proceeding) is asserted by such director, officer, or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue. |
| II-3 |
SIGNATURES
Pursuant to the requirements of the Securities Act, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-3 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Morristown, New Jersey, on November 18, 2026.
| ABEONA THERAPEUTICS INC. | ||
| By: | /s/ Joseph Vazzano | |
Joseph Vazzano Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer) | ||
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Vishwas Seshadri and Joseph Vazzano, and each of them, severally, as his or her true and lawful attorney or attorneys-in-fact and agent, with full power of substitution and resubstitution, for him or her and in his or her name, place, and stead, in any and all capacities, to sign any and all amendments to this Registration Statement (including all pre-effective and post-effective amendments and registration statements filed pursuant to Rule 462 under the Securities Act of 1933, as amended), and to file the same with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent full power and authority to do and perform each act and thing requisite and necessary to be done, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Act, this registration statement has been signed by the following persons in the capacities and on the dates indicated.
| Signature | Title | Date | ||
| /s/ Vishwas Seshadri | Chief Executive Officer and Director (Principal Executive Officer) | November 18, 2026 | ||
| Vishwas Seshadri | ||||
| /s/ Joseph Vazzano | Chief Financial Officer | November 18, 2026 | ||
| Joseph Vazzano | (Principal Financial Officer and Principal Accounting Officer) | |||
| /s/ Leila Alland | Director | November 18, 2026 | ||
| Leila Alland | ||||
| /s/ Mark Alvino | Director | November 18, 2026 | ||
| Mark Alvino | ||||
| /s/ Faith Charles | Director | November 18, 2026 | ||
| Faith Charles | ||||
| /s/ Eric Crombez | Director | November 18, 2026 | ||
| Eric Crombez | ||||
| /s/ Keith Goldan | Director | November 18, 2026 | ||
| Keith Goldan | ||||
| /s/ Donald Wuchterl | Director | November 18, 2026 | ||
| Donald Wuchterl | ||||
| /s/ Bernhardt Zeiher | Director | November 18, 2026 | ||
| Bernhardt Zeiher |
| II-4 |